Income before deduction of interest, taxes and amortization: uniqure.com (QURE)
uniQure N.V. (QURE) maintains business resilience through a safe liquidity buffer and the development of new pipelines. The operating cash flow volume visualizes this trend, where the 0.00 mark serves as a key metric. Revenues rely on royalties from HEMGENIX sales via CSL Behring. Supply reliability is guaranteed by strict temperature controls and isolation during the transport of drugs to specialized centers.
uniQure Pharma - analytical breakdowns and key metrics (QURE)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
- earnings and market multiples details:
QURE - Net Income|Projected Future Earnings uniQure N.V.|QURE - Price to Earnings Ratio|Future Price to Earnings Multiple uniQure|QURE - PEG Multiple|Company Value to EBITDA uniQure N.V.|QURE - Operating profit EBITDA|Earnings per share for the last 12 months uniQure|QURE - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months uniqure.com|QURE - Earnings growth in current year|Earnings growth forecast for next year uniQure N.V.
- sales and revenue indicators:
Fundamental company valuation:uniQure (QURE)
The investment attractiveness of uniQure N.V. (QURE) depends on its ability to generate internal resources amid biotech sector volatility. This metric measures the actual cash flow from core operations before interest and taxes, reflecting the fundamental efficiency of the business. By analyzing the operating cash result on GURU.Markets, an investor assesses the company's resilience to geopolitical risks and disruptions in European supply chains. Growth in this indicator confirms the ability to fund clinical trials without external borrowing. Stable positive dynamics guarantee capital preservation and long-term growth.
Competitor analysis for uniQure N.V.
Operating income before deduction of amortization Tempus AI Inc (TEM)|QGEN - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization IONS (Ionis Pharmaceuticals, Inc.)|RGEN: Operating profit EBITDA|Avidity - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization CRSP|Profit before interest, taxes and amortization genedx.com WGS|Operating profit before deduction of amortization RARE (Ultragenyx Corp)|BEAM (Beam Therapeutics) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta Therapeutics Inc)|Operating income before deduction of amortization Twist Bio (TWST)|TXG: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Therapeutics)|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|BioLife Corp (BLFS) - Operating profit EBITDA|WVE (wavelifesciences.com) - Operating profit EBITDA|Operating profit EBITDA Maze Therapeutics Inc|Operating profit EBITDA SION|PRME - Profit before interest, taxes and amortization|Operating profit EBITDA TSHA (Taysha Corp)|MGTX: Operating profit before amortization|REGENXBIO Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Solid Corp|Ocugen (OCGN) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Pacific Biosciences|Operating profit before deduction of amortization BNTC|Operating profit before deduction of amortization Design Therapeutics Inc (DSGN)|Operating profit EBITDA RCKT|Operating profit EBITDA 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Operating profit before deduction of amortization|KRRO: Operating profit before amortization|Editas Corp - Operating profit EBITDA|SLN: Profit before payment of interest, taxes and amortization|PRQR (ProQR) - Operating profit before deduction of amortization|Operating profit before amortization CDXS|Profit before payment of interest, taxes and amortization sangamo.com|Operating profit before amortization NAUT (Nautilus Biotechnology)|Operating profit EBITDA MGX|Operating income before deduction of amortization Precision BioSciences Inc.|Operating profit EBITDA GBIO (Generation Bio Co)|Operating profit EBITDA Boundless Bio, Inc BOLD|Exicure Corp - Operating profit EBITDA|Operating income before deduction of amortization Imunon IMNN|PHIO: Operating profit EBITDA|MBIO: Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization TransCode Therapeutics, Inc.|Operating profit EBITDA Bionano Genomics, Inc.|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Profit before payment of interest, taxes and amortization BLUE (bluebird bio, Inc.)|Operating profit EBITDA IPA (immunoprecise.com)|Operating profit EBITDA Omega OMGA|OMIC - Profit before payment of interest, taxes and amortization|RGLS - Operating profit EBITDA|Syros Pharmaceuticals Inc. (SYRS) - Profit before payment of interest, taxes and amortization|TBIO (Telesis Bio, Inc.) - Profit before payment of interest, taxes and amortization|TCON (TRACON Pharmaceuticals Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Unity Bio UBX
